Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR

31 Jul 2025

Abstract excerpt

Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations. Targeted therapy for malignant melanoma with BRAF inhibitor (BRAFi) or its combination with MEK inhibitor (MEKi) improves the clinical outcomes of patients, but resistance develops invariably. The underlying mechanisms remain incompletely understood. Here, we show that caveolae number is increased in both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caveolin-1 and cellular processes
Share to Cell Adhesion Molecules Research
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40745979
DOI: 10.1111/cpr.70086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFRPMID 40745979Read ↗

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell linesSemantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current KnowledgeSemantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.